AT1
Director Trades
| Date | Director | Value |
|---|
Company News
Atomo Diagnostics to supply HIV test kits across SA and Victoria as part of national vending machine program
Atomo Diagnostics (ASX: AT1) has received a $230,000 order from Thorne Harbour Health for HIV Self Test kits to support a national scale-up of the federal government’s CONNECT program, which provides free kits through vending machines. Thorne’s order will supply kits to machines across South Australia and Victoria as part of the government’s pilot program […]
Weekly wrap: WiseTech relief rally helps market to bounce higher
After days of fairly salacious headlines around WiseTech founder Richard White and his penchant for delivering mansions to girlfriends, the company pushed the entire Australian market into making a small gain. News that Mr White would step aside as chief executive but will return in a full-time product and business development consulting role led to […]
Atomo Diagnostics secures $2.44m grant to develop first rapid active syphilis self-test
Atomo Diagnostics (ASX: AT1) has again been recognised by the Australian government with the award of a $2.44 million grant to develop a unique syphilis test. The Australian-based medical device company was awarded the CRC-P industry grant from the Department of Industry, Science and Resources (DISR) to support the development of an innovative rapid active […]
Atomo Diagnostics boosted by federal funding for HIV prevention and self-test expansion
Medical device company Atomo Diagnostics (ASX: AT1) has welcomed the Australian government’s commitment to fund the expansion of self-testing procedures for human immunodeficiency virus (HIV) in this week’s federal budget. The company anticipates that a significant portion of the $43.9 million committed to HIV prevention will be used for the procurement of more of its […]
Atomo Diagnostics partners with Viatris Healthcare, secures $970k order for HIV self-test kits
Atomo Diagnostics (ASX: AT1) has secured purchase orders from global health partner Viatris Healthcare for approximately $970,000 worth of self-test kits for the detection of human immunodeficiency virus (HIV). The kits will be manufactured by Atomo under the Mylan brand for supply to a number of low and middle-income countries. The order will be fulfilled […]
Atomo Diagnostics and NG Biotech to commercialise blood-based rapid pregnancy tests
Under a new commercialisation agreement, Atomo Diagnostics (ASX: AT1) and NG Biotech will launch a unique blood-based rapid pregnancy tests across Australia, New Zealand, Canada and the United States. The new pregnancy test combines NG Biotech’s manufactured “highly sensitive hCG test assay” and Atomo’s integrated Pascal blood test device. Detectable hCG levels are known to […]
Atomo Diagnostics receives TGA approval to supply COVID-19 antibody test kit to Australian market
Medical device company Atomo Diagnostics (ASX: AT1) has received approval from the Therapeutic Goods Administration for its AtomoRapid (IgG/IgM) antibody test kit for patients with suspected COVID-19. The test is able to determine if a patient has developed antibodies to the virus and can obtain results from a drop of blood within 15 minutes. TGA […]
Atomo Diagnostics partners with US biotech for global marketing of COVID-19 rapid test kits
Newly-listed medical device company Atomo Diagnostics (ASX: AT1) has signed a binding agreement with US-based Access Bio Inc which will allow for the supply of Atomo’s Galileo rapid diagnostic test (RDT) device for use with Access’ rapid test strips for the detection of COVID-19 antibodies. Access currently offers a standard COVID-19 rapid blood-based test using […]
Atomo Diagnostics secures exclusive rights to market COVID-19 antibody test
Medical device company Atomo Diagnostics (ASX: AT1) has penned a supplementary deal with existing business partner NG Biotech that could see over 2 million additional COVID-19 antibody tests being sold by the end of the year. The news comes hot on the heels of a recent French study carried out at the Hopital Bicêtre in […]
Atomo Diagnostics secures COVID-19 test device orders ahead of ASX listing
On the eve of its ASX debut, biotech company Atomo Diagnostics (ASX: AT1) has revealed it has received additional orders for its proprietary rapid blood test devices being used to test for COVID-19. The company today announced a second purchase order from French diagnostics company NG Biotech to supply a further 550,000 devices to test […]